Metagenomi, Inc.
MGX
$2.07
$0.136.70%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 45.13% | 83.36% | 109.93% | 160.21% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.13% | 83.36% | 109.93% | 160.21% | -- |
| Cost of Revenue | 30.77% | 61.16% | 92.76% | 118.83% | -- |
| Gross Profit | -19.12% | -43.61% | -80.80% | -91.40% | -- |
| SG&A Expenses | 20.05% | 38.05% | 46.51% | 54.24% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.16% | 55.21% | 79.84% | 99.30% | -- |
| Operating Income | -19.46% | -41.48% | -67.20% | -75.83% | -- |
| Income Before Tax | -31.50% | -50.83% | -54.59% | -46.81% | -- |
| Income Tax Expenses | -125.69% | -68.90% | 38.15% | 212.46% | -- |
| Earnings from Continuing Operations | -16.30% | -38.51% | -53.21% | -56.57% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.30% | -38.51% | -53.21% | -56.57% | -- |
| EBIT | -19.46% | -41.48% | -67.20% | -75.83% | -- |
| EBITDA | -18.47% | -40.46% | -65.70% | -73.13% | -- |
| EPS Basic | 53.26% | 4.78% | -4.05% | -69.37% | -- |
| Normalized Basic EPS | 54.63% | 6.16% | -5.42% | -62.64% | -- |
| EPS Diluted | 53.24% | 4.76% | -4.07% | -69.39% | -- |
| Normalized Diluted EPS | 54.63% | 6.16% | -5.42% | -62.64% | -- |
| Average Basic Shares Outstanding | 423.59% | 245.35% | 125.81% | 0.23% | -- |
| Average Diluted Shares Outstanding | 423.59% | 245.35% | 125.81% | 0.23% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
